US$ 26.76
nafld and glutathione liposomal nonalcoholic fatty liver disease Nonalcoholic fatty liver disease: Current therapies future perspectives in drug delivery In vitro models for non-alcoholic
Description
Trong trng hp khng ti ch c glutathione th c th s gp phi tnh trng qu ti vi cht c v dn ti v mc cn bng sn c

Update on genetic predisposition to colorectal cancer and polyposis

SM22alpha loss contributes to apoptosis of vascular smooth muscle cells via macrophage-derived circRasGEF1B
Genet Test Mol Biomarkers
